Form 4: Edgewise Therapeutics CEO Kevin Koch Executes Stock Option and Sells Shares

CEO Kevin Koch exercised stock options and sold shares of Edgewise Therapeutics, Inc. on February 5th and 6th, 2025, according to a Form 4 filing.

Summary

• On February 5, 2025, Kevin Koch, the President and CEO of Edgewise Therapeutics, exercised stock options to acquire 8,636 shares of common stock at $0.18 per share and sold the same amount at an average price of $30.0252 per share.
• On February 6, 2025, Koch exercised options for 900 shares at $13.11 and sold them at an average price of $31.1311.
• The sales were executed under a Rule 10b5-1 plan adopted on September 30, 2024.
• Following these transactions, Koch directly owns 14,478 shares and indirectly owns 259,554 shares through KTK Family Enterprise, LLC, as well as 26,410 shares each through the Nicole M. Soldow Heritage Trust, Adrienne R. Koch Heritage Trust, and Matthew K. Koch Heritage Trust.
• He also directly owns 41,645 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions. The use of a 10b5-1 plan suggests pre-planned activity, reducing potential negative interpretations.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Insider trading activity is common across publicly listed companies, and the legality hinges on compliance with regulations like Rule 10b5-1, which allows insiders to establish pre-arranged trading plans to avoid accusations of trading on non-public information.
• The size and frequency of insider transactions can vary widely depending on the company's size, industry, and individual circumstances.
• Comparing Koch's transactions to those of CEOs at similar-stage biotech companies would require analyzing their Form 4 filings over a comparable period.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price due to the sales.
• However, the pre-planned nature of the transactions mitigates concerns about insider information being used.

Key Dates

Keywords

Form 4, insider trading, stock options, share sales, Kevin Koch, Edgewise Therapeutics, EWTX